| Company type | Subsidiary |
|---|---|
| Nasdaq: PCYC | |
| Industry | Biopharmaceutical |
| Founded | 1991 |
| Founders | Jonathan Sessler, Richard A. Miller [1] |
| Headquarters | Sunnyvale, California |
Area served | Worldwide |
Key people | Robert Duggan, former CEO and Chairman |
| Revenue |  US$235 million (2013)
[2] |
| US$110 million (2013)
[2] | |
| US$86.1 million (2013)
[2] | |
| Total assets | US$1.06 billion (2013)
[2] |
| Total equity | US$829 million (2013)
[2] |
| Parent | AbbVie |
| Website |
pharmacyclics |
Pharmacyclics LLC is an American biopharmaceutical company based in Sunnyvale, California. It is primarily focused on the development of cancer therapies. [3] [4] In 2017, Xynomic Pharmaceuticals acquired all global rights to Abexinostat, Pharmacyclics' primary commercial product. [5]
Acquisition by AbbVie
In March 2015, Chicago-based biopharmaceutical firm AbbVie announced it would acquire Pharmacyclics, as well as its lead anti-cancer compound ibrutinib (Imbruvica) for $21 billion. As part of the deal, AbbVie will pay $261.25 per share in a mixture of both cash and AbbVie equity. [6] The merger is expected to close in mid-2015. [7]
Duggan will receive over $3.55 billion from the sale of Pharmacyclics to AbbVie in "one of the biggest paydays ever from the buyout of a publicly held company." [8] [9] [10] [11] [12]
As CEO and chairman of Pharmacyclics since 2008, Robert Duggan has opted not to receive compensation from the company. [8]
References
- ^ Lee Clippard (2006). "Professor's personal battle leads to development of new cancer drug". University of Texas. Retrieved May 30, 2015.
- ^ a b c d e "Shangri-La Hotels and Resorts Annual report 2019-20" (PDF). Shangri-La Hotels and Resorts. Shangri-La Hotels and Resorts Asia.
- ^ Sawyer, Anthony (25 January 2018). "Pharmacyclics (PCYC) Given Daily Media Impact Score of 0.42". Week Herald. Retrieved 29 January 2018.
- ^ "Pharmacyclics Inc. (PCYC)". Yahoo. Retrieved May 30, 2015.
- ^ "Xynomic Acquires Global Rights to Anticancer Drug Abexinostat". Genetic Engineering & Biotechnology News. February 24, 2017. Retrieved February 25, 2017.
- ^ Staff (5 March 2015). "AbbVie Acquires Oncology Drug Firm Pharmacyclics for $21B". Genetic Engineering & Biotechnology News.
- ^ "Ex-99.1".
- ^ a b Gary Strauss (March 24, 2015). "The $3.55 billion Man". USA Today. Archived from the original on 2015-07-24.
- ^ Antoine Gara. "Robert Duggan". Forbes.
- ^ "Pharmacyclics May Soon Be Acquired by Johnson & Johnson for $18 Billion". Science Times. 3 March 2015.
- ^ "The Hiring Guru: Robert Duggan Billionaire". The Huffington Post. 18 April 2014.
- ^ Sean Williams (27 February 2013). "This Is One Incredible CEO". fool.com.
External links
- Historical business data for Pharmacyclics:
- SEC filings
| Company type | Subsidiary |
|---|---|
| Nasdaq: PCYC | |
| Industry | Biopharmaceutical |
| Founded | 1991 |
| Founders | Jonathan Sessler, Richard A. Miller [1] |
| Headquarters | Sunnyvale, California |
Area served | Worldwide |
Key people | Robert Duggan, former CEO and Chairman |
| Revenue | US$235 million (2013)
[2] |
| US$110 million (2013)
[2] | |
| US$86.1 million (2013)
[2] | |
| Total assets | US$1.06 billion (2013)
[2] |
| Total equity | US$829 million (2013)
[2] |
| Parent | AbbVie |
| Website |
pharmacyclics |
Pharmacyclics LLC is an American biopharmaceutical company based in Sunnyvale, California. It is primarily focused on the development of cancer therapies. [3] [4] In 2017, Xynomic Pharmaceuticals acquired all global rights to Abexinostat, Pharmacyclics' primary commercial product. [5]
Acquisition by AbbVie
In March 2015, Chicago-based biopharmaceutical firm AbbVie announced it would acquire Pharmacyclics, as well as its lead anti-cancer compound ibrutinib (Imbruvica) for $21 billion. As part of the deal, AbbVie will pay $261.25 per share in a mixture of both cash and AbbVie equity. [6] The merger is expected to close in mid-2015. [7]
Duggan will receive over $3.55 billion from the sale of Pharmacyclics to AbbVie in "one of the biggest paydays ever from the buyout of a publicly held company." [8] [9] [10] [11] [12]
As CEO and chairman of Pharmacyclics since 2008, Robert Duggan has opted not to receive compensation from the company. [8]
References
- ^ Lee Clippard (2006). "Professor's personal battle leads to development of new cancer drug". University of Texas. Retrieved May 30, 2015.
- ^ a b c d e "Shangri-La Hotels and Resorts Annual report 2019-20" (PDF). Shangri-La Hotels and Resorts. Shangri-La Hotels and Resorts Asia.
- ^ Sawyer, Anthony (25 January 2018). "Pharmacyclics (PCYC) Given Daily Media Impact Score of 0.42". Week Herald. Retrieved 29 January 2018.
- ^ "Pharmacyclics Inc. (PCYC)". Yahoo. Retrieved May 30, 2015.
- ^ "Xynomic Acquires Global Rights to Anticancer Drug Abexinostat". Genetic Engineering & Biotechnology News. February 24, 2017. Retrieved February 25, 2017.
- ^ Staff (5 March 2015). "AbbVie Acquires Oncology Drug Firm Pharmacyclics for $21B". Genetic Engineering & Biotechnology News.
- ^ "Ex-99.1".
- ^ a b Gary Strauss (March 24, 2015). "The $3.55 billion Man". USA Today. Archived from the original on 2015-07-24.
- ^ Antoine Gara. "Robert Duggan". Forbes.
- ^ "Pharmacyclics May Soon Be Acquired by Johnson & Johnson for $18 Billion". Science Times. 3 March 2015.
- ^ "The Hiring Guru: Robert Duggan Billionaire". The Huffington Post. 18 April 2014.
- ^ Sean Williams (27 February 2013). "This Is One Incredible CEO". fool.com.
External links
- Historical business data for Pharmacyclics:
- SEC filings